XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 43.06

Change

-0.43 (-0.99)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.46 (-1.03%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

-0.65 (-0.97%)

USD 2.62B
FXH First Trust Health Care AlphaD..

-0.50 (-0.47%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

-0.58 (-0.64%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.39 (-1.78%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.69 (-2.25%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.29 (-0.31%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

-0.48 (-1.62%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.15 (-1.91%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.58 (-2.63%)

USD 8.55M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.93 % 0.00 %

+0.19 (+0.69%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.16% 33% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.16% 33% F 60% D-
Trailing 12 Months  
Capital Gain 2.43% 57% F 46% F
Dividend Return 1.62% 100% F 26% F
Total Return 4.04% 67% D+ 37% F
Trailing 5 Years  
Capital Gain -10.12% 24% F 40% F
Dividend Return 5.36% 68% D+ 15% F
Total Return -4.76% 24% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain -1.63% 19% F 25% F
Dividend Return -0.89% 19% F 17% F
Total Return 0.74% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.95% 67% D+ 65% D
Risk Adjusted Return -5.58% 14% F 17% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.